ABAlain Bernady

Alain Bernady

*This is an algorithmically generated author record based on publicly available information.

Alain Bernady has a total of 31 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Sex Differences and Survival Among COPD Patients in France: The Palomb Cohort

    by Nolwenn Jestin-Guyon, El Hassane Ouaalaya, Alain Bernady, Emilie Berteaud, Zamira Betancourt-Rial, Jean Moinard, Laurent Falque, Frédéric Le Guillou, Mathieu Molimard, Laurent Nguyen, et al.

    Purpose: Previous studies suggest that the clinical presentation of chronic obstructive pulmonary disease (COPD) is different between men and women. The aim of this study was to investigate sex-related differences and survival among COPD patients. Patients and Methods: Multicentric prospective real-life cohort. COPD patients (post-bronchodilator FEV1/FVC < 0.7) of any stages of airway obstruction recruited since January 2014 by pulmonologists. Stratified logistic regression models assessed to identify the determinants of dyspnea, exacerbations, ABE classification and all-cause mortality by sex. Kaplan–Meier curves and Cox proportional-hazards models were also performed. Results: A total of 3265 patients included, with 36.7% women. Women had an increased risk of ≥ 2 exacerbations (aOR=1.79; 95%CI[1.46– 2.19]), mMRC grade 1 (aOR=1.46; 95%CI[1.14– 1.89]) and grade 2 (aOR=1.41; 95%CI[1.07– 1.87]) and a higher risk of severity E of the ABE classification (aOR=1.56; 95%CI[1.27– 1.93]). In stratified models, the determinants of these outcomes were different. Men had a lower survival rate at GOLD airway obstruction I–II (Log-rank: p< 0.0001) and III–IV (Log-rank: p< 0.0001) and a higher risk of mortality (HR=1.62; 95%CI[1.40– 1.87]). Common factors characterizing mortality were: age, BMI < 18.5, mMRC ≥ 2, airway obstruction, diabetes and lung cancer. Additional factors related to mortality in men were asthma, left heart failure and tobacco-related cancers. Conclusion: COPD is more severe in women however men have a higher risk of mortality. Clinical features and mortality in men and women with COPD are different in our cohort. Further studies are needed to elucidate sex-related differences among COPD patients.

  • Open Access

    Translation and Cultural Adaptation of PROactive Instruments for COPD in French and Influence of Weather and Pollution on Its Difficulty Score

    by Trija Vaidya, Véronique Thomas-Ollivier, François Hug, Alain Bernady, Camille Le Blanc, Claire de Bisschop, Arnaud Chambellan

    Introduction: The recently developed daily and clinical visit PROactive physical activity in COPD (PPAC) instruments are hybrid tools to objectively quantify the level of physical activity and the difficulties experienced in everyday life. Our aim was to translate these instruments for the French-speaking chronic obstructive pulmonary disease (COPD) community worldwide and evaluate the influence of weather and pollution on difficulty score. Methods: The translation procedure was conducted following the guidelines for cross-cultural adaptation process. The translated clinical visit (C-PPAC) was tested among COPD patients in France. A retest was conducted after an interval of at least 2 weeks. The C-PPAC difficulty score was then tested to see how sensitive it was to the influence of weather and outdoor pollution. Results: One hundred and seventeen COPD patients (age 65± 9 years; FEV1: 51± 20%) from 9 regions in France were included. The French version of C-PPAC was found comprehensible by the patients with an average score of 4.8/5 on a Likert-scale. It showed good internal consistency with Cronbach’s α> 0.90 and a good test retest reliability with an intraclass correlation coefficient of ≥ 0.80. The difficulty score was negatively correlated with duration of daylight (ρ=− 0.266; p< 0.01) and influenced by the intensity of rainfall (light vs. heavy rainfall: 68± 16 vs. 76± 14 respectively, p=0.045). The score was lower in patients receiving long term oxygen therapy (60± 15 vs. 71± 15, p< 0.01), but not correlated with the pollution indices. Conclusion: The French versions of the questionnaires of the PPAC instruments are accepted and comprehensible to COPD patients. The difficulty score of C-PPAC is sensitive to duration of daylight and rainfall. Such weather factors must be taken into consideration when evaluating the physical activity behavior using these tools in COPD.


  • Open Access

    Minimal clinically important difference of 3-minute chair rise test and the DIRECT questionnaire after pulmonary rehabilitation in COPD patients

    by Jonathan Lévesque, Anestis Antoniadis, Pei Zhi Li, Frédéric Herengt, Christophe Brosson, Jean-Marie Grosbois, Alain Bernady, Anthony Bender, Murielle Favre, Antoine Guerder, et al.

    Background: The 3-minute chair rise test (3-minute CRT) and the Disability Related to COPD Tool (DIRECT) are two reproducible and valid short tests that can assess the benefit of pulmonary rehabilitation (PR) in terms of functional capacity and dyspnea in everyday activities. Methods: We determined the minimal clinically important difference (MCID) of the DIRECT questionnaire and 3-minute CRT using distribution methods and anchor encroaches with a panel of eight standard tests in a cohort of 116 COPD patients who completed a PR program in real-life settings. Results: The estimated MCID for the 3-minute CRT and DIRECT scores was five repetitions and two units, respectively, using separate and combined independent anchors. The all-patient (body mass index-obstruction-dyspnea-exercise [BODE] scores 0–7), BODE 0–2 (n=42), and BODE 3–4 (n=50) groups showed improvements greater than the MCID in most tests and questionnaires used. In contrast, the BODE 5–7 group (n=24) showed improvements greater than MCID in only the 3-minute CRT, 6-minute walk test, endurance exercise test, and DIRECT questionnaire. Discussion and conclusion: This study demonstrates that the short and simple DIRECT questionnaire and 3-minute CRT are responsive to capture the beneficial effects of a PR program in COPD patients, including those with severe disease. Trial registration number: NCT03286660.